< Back to Find a Trial Assessment of Safety, Tolerability and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease (18G-MC-LMDC) ID NCT03518073 Condition Studied Alzheimer's Disease Phase Phase II Status Closed Intervention LY3303560 Principal Investigator Julio Rojas, MD, PhD [email protected] 415-502-7341 Sponsor Eli Lilly and Company Contact Coordinator Lisa Romero [email protected] 415-476-0700 Please go to ClinicalTrials.gov for more information.